$Supernus Pharmaceuticals (SUPN.US)$In the past 5 years, wit...
$Supernus Pharmaceuticals(SUPN.US$In the past 5 years, with the exception of 2019, revenue grew at an average rate of 17%. Instead, after 3 years of growth, operating profit fell sharply by 54.7% in 2021 and continued to decline sharply by 42.6% in 2022, mainly due to a sharp increase in operating expenses.
After checking the balance sheet, goodwill certainly increased from 442 million to 902 million in 2021. This acquisition caused a sharp decline in the company's operating efficiency, which has not abated until now.
Revenue increased 0.8% in 2023Q1, operating profit increased 34% to 3.53 million on a very low basis, and net profit shrank 34% due to a sharp decline in interest income.
Currently, the price-earnings ratio is 32.2 and the price-earnings ratio is TTM 37.2. There is no investment value until operational efficiency is improved.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
